Two Sigma Securities’s Co-Diagnostics CODX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,026
Closed -$5.19K 1729
2025
Q4
$5.19K Buy
+1,026
New +$11.2K ﹤0.01% 1337
2025
Q2
Sell
-980
Closed -$9.1K 1586
2025
Q1
$9.1K Buy
980
+431
+79% +$8.24K ﹤0.01% 1244
2024
Q4
$12.3K Buy
+549
New +$17.3K ﹤0.01% 1408
2024
Q3
Sell
-587
Closed -$22K 2983
2024
Q2
$22K Buy
+587
New +$21.4K ﹤0.01% 2683
2024
Q1
Sell
-539
Closed -$21.5K 3048
2023
Q4
$21.5K Sell
539
-15
-3% -$529 ﹤0.01% 2713
2023
Q3
$17.6K Buy
+554
New +$20.9K ﹤0.01% 2594
2022
Q4
Sell
-512
Closed -$49K 2672
2022
Q3
$49K Buy
+512
New +$71.6K ﹤0.01% 2185
2018
Q1
Sell
-339
Closed -$28K 2691
2017
Q4
$28K Buy
+339
New +$50.8K ﹤0.01% 1596

Other funds holding CODX

Two Sigma Securities's CODX Position: Q1 2026 in Review

Two Sigma Securities sold out of Co-Diagnostics (CODX) in Q1 2026, closing a stake of 1,026 shares — an estimated $5.19K sold.

Two Sigma Securities first reported a position in CODX in Q4 2017 and held it in 8 quarters. The position peaked at $49K in Q3 2022. 14 funds tracked by Wall St. Rank hold CODX as of Q1 2026.

  • Two Sigma Securities reported no remaining Co-Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 1,026 Co-Diagnostics shares in Q1 2026, an estimated $5.19K.
  • Two Sigma Securities first reported a position in Co-Diagnostics in Q4 2017 and held it in 8 quarters.
  • Two Sigma Securities's Co-Diagnostics position peaked at $49K in Q3 2022.
  • 14 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.